12 High Growth Large Cap Stocks to Buy Now

4) BeiGene, Ltd. (NASDAQ:BGNE)

5-Year Revenue Growth: ~48.1%

Average Upside Potential: ~45.6%

Market cap as of 12 November: $20.5 billion

BeiGene, Ltd. (NASDAQ:BGNE) is an oncology company, which is engaged in discovering and developing various treatments for cancer patients in the US and internationally.

BeiGene, Ltd. (NASDAQ:BGNE)’s in-house clinical operations team carries out trials throughout 5 continents, ensuring rigorous data quality via collaborations with regulators and investigators in more than 45 countries. This strategic approach tends to maximize resources by channeling data-gated investments into promising clinically differentiated candidates quickly and de-prioritizing others.

BeiGene, Ltd. (NASDAQ:BGNE)’s unique R&D and clinical advantages, together with the tremendous launch trajectory of BRUKINSA, should continue to strengthen the company’s global oncology leadership. In the US, BRUKINSA, with the broadest label of any BTK inhibitor, is the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL in addition to other approved B-cell malignancies.

In the solid tumor area, BeiGene, Ltd. (NASDAQ:BGNE) continues to expand its access to the PD-1 inhibitor, TEVIMBRA, for patients worldwide and is building global commercial capabilities to aid its prolific pipeline of potential cancer medicines.

BeiGene, Ltd. (NASDAQ:BGNE) has been laying the foundation for future franchises in breast, lung, and gastrointestinal cancers across 3 signature platform technologies such as multi-specific antibodies, protein degraders, and antibody-drug conjugates. Also, strategic partnerships with industry giants such as Amgen and Novartis fueled the commercial capabilities. In Q3 2024, it saw revenues of $1,002 million as compared to $781 million in the same period of 2023. This increase mainly stemmed from growth in BRUKINSA product sales in the US and Europe of 87% and 217% respectively.

Citigroup upped its price objective on shares of BeiGene, Ltd. (NASDAQ:BGNE) from $269.00 to $288.00, giving a “Buy” rating on 8^th August. Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the third-quarter 2024 investor letter. Here is what the fund said:

“BeiGene, Ltd. (NASDAQ:BGNE) is expected to have excellent top- and bottom-line growth over the next several years, driven by Brukinsa, their best-in-class product in several hematology cancers, with a global market size of approximately $9 billion in 2023. Even though the company is truly global in nature, incorporated in Switzerland and headquartered in Basal, Beijing, and Cambridge, MA, its valuation was depressed due to negative sentiment towards China, as it does have a large R&D and sales team in China. The recent rally in China stocks has somewhat reduced the extreme pessimism seen earlier in the year.”